Home › Companies › PMN

ProMIS Neurosciences

Market cap $28.9M 9.0M shares (10-Q, Nov 12, 2026) × $3.21 close Nov 17, 2026

Most recent annual filing: 2026-03-25

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. PMN310 FDA feedback2H 2026PMN310 FDA feedback, 2H 2026, notable
  2. PMN310 corporate update2H 2026PMN310 corporate update, 2H 2026, routine
  3. PMN310 topline1Q 2027PMN310 topline, 1Q 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Technology platforms

EpiSelect · University of British Columbia

Computational discovery platform using thermodynamics and statistical mechanics to model protein misfolding and identify disease-specific conformational epitopes on toxic misfolded proteins. Used to generate selective monoclonal antibodies, intrabodies, and therapeutic vaccines targeting neurodegenerative and misfolded protein diseases including Alzheimer's disease, ALS, Parkinson's disease, MSA, DLB, frontotemporal dementia, and schizophrenia.

Targets: amyloid beta oligomers, alpha-synuclein, TDP-43, tau, SOD1, RACK1, DISC1

EpiSelect

Computational platform to identify conformational epitopes (Disease Specific Epitopes / DSEs) uniquely exposed on toxic misfolded proteins, used to generate misfolding-specific antibodies and vaccine candidates; disease focus: Alzheimer's disease, ALS, frontotemporal dementia, multiple system atrophy, Parkinson's disease

Targets: amyloid-beta oligomers, TDP-43, alpha-synuclein, Aβ oligomers

TXP1 · Ossianix

Next-generation brain-selective shuttling technology based on a deimmunized, single-domain VNAR antibody scaffold targeting transferrin receptor 1 (TfR1); enables enhanced CNS delivery of therapeutic antibodies; focus area: Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative diseases

Targets: TfR1

Capital (as filed)

Cash
$44.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$34K Sep 30, 2026
Operating cash flow
−$9.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$44.1M cash, runway through 2027 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on ProMIS Neurosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch ProMIS Neurosciences (PMN) — Scientific Deep Dive for PMN310 and Pipeline Products The oligomer thesis is coherent and the syndicate is elite, but PMN310 has zero human efficacy data and Acumen's sabirnetug reads out first, making the cost of waiting opportunity rather than principal.
  2. Watch UPDATE: ProMIS Neurosciences (PMN) - The Interim Gets a Date The blinded interim is a safety confirmation the market has already granted rather than the efficacy read the story needs, and the two gating events that actually change risk/reward arrive later.
  3. Speculative buy speculative UPDATE: ProMIS Neurosciences (PMN) - The Low-Information Print That Wasn't Safety differentiation is now an observed human result in the highest-ARIA-risk genotypes and two independent tau-pathway markers moved favorably against rising natural history, warranting a starter speculative position.
  4. Watch UPDATE: ProMIS Neurosciences (PMN) - Someone Else's Exam, ProMIS's Grade Sabirnetug failed cleanly in the first large test of oligomer selectivity against a clinical endpoint, destroying the class thesis that underpinned the upgrade, despite PMN310's own data being unchanged.
  5. Watch UPDATE: ProMIS Neurosciences (PMN) - The Rebuttal Deck ProMIS's case that PMN310 differs from sabirnetug is coherent but untested, the FDA meeting has slipped past the data, and the thesis gets tested at Q1 2027 topline with nothing in the new filings changing the read.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (26)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

18 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)